Abdel-Hady, Y., Aly El-Wakil, M., Abd El-Meguid, K., Abosaif, K. (2022). Value of Left Ventricular Global Longitudinal Strain Assessed by Two-Dimensional Strain Imaging in Early Detection of Anthracycline Mediated Cardiotoxicity. test, 3(2), 23-47. doi: 10.21608/ejmr.2022.231679
Yasser Ahmed Abdel-Hady; Mohamed Aly El-Wakil; Khaled Refaat Abd El-Meguid; Khadiga Mohamed Abosaif. "Value of Left Ventricular Global Longitudinal Strain Assessed by Two-Dimensional Strain Imaging in Early Detection of Anthracycline Mediated Cardiotoxicity". test, 3, 2, 2022, 23-47. doi: 10.21608/ejmr.2022.231679
Abdel-Hady, Y., Aly El-Wakil, M., Abd El-Meguid, K., Abosaif, K. (2022). 'Value of Left Ventricular Global Longitudinal Strain Assessed by Two-Dimensional Strain Imaging in Early Detection of Anthracycline Mediated Cardiotoxicity', test, 3(2), pp. 23-47. doi: 10.21608/ejmr.2022.231679
Abdel-Hady, Y., Aly El-Wakil, M., Abd El-Meguid, K., Abosaif, K. Value of Left Ventricular Global Longitudinal Strain Assessed by Two-Dimensional Strain Imaging in Early Detection of Anthracycline Mediated Cardiotoxicity. test, 2022; 3(2): 23-47. doi: 10.21608/ejmr.2022.231679

Value of Left Ventricular Global Longitudinal Strain Assessed by Two-Dimensional Strain Imaging in Early Detection of Anthracycline Mediated Cardiotoxicity

Egyptian Journal of Medical Research
Article 2, Volume 3, Issue 2, April 2022, Pages 23-47    PDF (840.27 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.231679
Authors
Yasser Ahmed Abdel-Hady1; Mohamed Aly El-Wakil2; Khaled Refaat Abd El-Meguid1; Khadiga Mohamed Abosaif1
1Cardiology department, Faculty of Medicine, Beni-Suef University, Egypt
2Oncology department, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
The goal of this study is to investigate whether alterations of myocardial global longitudinal strain and high‐sensitive cardiac troponin could be detected early in patients receiving anthracycline chemotherapy & if it could predict future cardiac dysfunction. Methods: Thirty patients with cancer treated with Adriamycin were studied. Blood collection for measurement of high sensitive troponin and echocardiography were performed at baseline, three months & six months of chemotherapy. Global longitudinal strain (GLS), were calculated using speckle tracking echocardiography. Left ventricular ejection fraction was measured by M-mode echocardiography.  Results: LVEF although reduced after treatment, remained within the normal range (65±3.6% at base line vs. 63±2.7% at three months vs. 62±2.6% at six months of treatment, p = 0.002).LVIDd & LVIDs was highest after 6 months of chemotherapy. GLS was significantly reduced after treatment (-20.56±1.9% vs. -18.2±2.2% at three months vs -17.1±2.1 at six months of treatment, p < 0.001). Subclinical LV dysfunction (>15% reduction in GLS compared to before therapy) occurred in 43%. Serum hs‐cTnI levels increased significantly after 3 months of treatment with anthracycline (0.0088± 0.012, vs. 0.345 ± 0.5 after three months of treatment, p = 0.001).There was positive correlation between EF & GLS while a negative correlation was found between hscTnI & GLS. Hs‐cTnI assays was significantly increased in patients with Drop in GLS as compared with patients with no Drop in GLS after 3 months follow-up. No statistically significant difference between drop in GLS or hs-cTnI levels and cumulative dose of anthracyclines. No clinical parameters were associated with the drop in GLS or elevation of hs‐cTnI levels. Conclusion: Measurement of LV GLS by 2D STE during & after anthracycline therapy combined with hs-cTnI assay may allow an early identification of cardiac damage and therefore provide a way to minimize cardiac related mortality and morbidity while undergoing chemotherapy and afterwards.
Keywords
Anthracycline; cardiotoxicity; global longitudinal strain
References
  1. Shaikh A. and Shih J. “Chemotherapy-induced cardiotoxicity.” Curr Heart Fail Rep. (2012); 9(2):117-27.
  2. Raj S., Franco V.and Lipshultz S. “Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment”. Curr Treat Options Cardiovasc Med (2014); 16:315.
  3. Shaikh A., McGuiness M. and Shih J. “Cardiovascular toxicity of newer chemotherapeutic agents the heart of the matter.” Oncology (Williston Park). (2014); 28(6):493- 496.
  4. Blum J., Flynn P. and Yothers G. “Anthracyclines in Early Breast Cancer”: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol (2017); 35:2647.
  5. Monsuez J., Charniot J., Vignat N. et al. “Cardiacside-effects of cancer chemotherapy.” Int J Cardiol. (2010); 144:3-15.
  6. Cardinale D., Colombo A. and Lamantia G. “Anthracycline-induced cardiomyopathy.” Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. (2010); 55(3):213-20.
  7. Claus, P., Omar, A., Pedrizzetti G. et al. “Tissue tracking technology for assessing cardiac mechanics” Principles, normal values, and clinical applications. JACC Imaging (2015), 8, 1444–1460.
  8. Thavendiranathan P., Poulin F. and Lim K. “Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy” a systematic review. J Am Coll Cardiol (2014); 63:2751.
  9. Lang R., Badano L. and Mor-Avi V. “Recommendations for cardiac chamber quantification by echocardiography in adults:” an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr (2015); 28:1.
  10. Zamorano J., Lancellotti P. and Rodriguez Muñoz. “2016 ESC Position Paper on cancer treatments and cardiovascular toxicity” developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J (2016); 37:2768.
  11. Curigliano G., Cardinale D. and Suter T. “Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy” ESMO Clinical Practice Guidelines. Ann Oncol (2012); 23 Suppl 7:vii155–vii166.
  12. Ky B., Putt M. and Sawaya H. “Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab”. J Am Coll Cardiol (2014); 63:809.
  13. De Lemos J., Drazner M., Omland T. et al. “Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.” JAMA (2010); 304:2503–2512.
  14. Yu K., Xiaoping X., Leilei C., et al “Two‐dimensional speckle tracking echocardiography combined with high‐sensitive cardiac troponin I in early detection and prediction of cardiotoxicity during epirubicine‐based chemotherapy European Journal of Heart Failure”  (2013) European Society of Cardiology.
  15. Motoki H., Koyama, J., Nakazawa, H. et al. “Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy.” Eur. Heart J. Cardiovasc. Imaging, (2012) 13(1): 95–103.
  16. Tsai, H., Gjesdal, O., Wethal, T., et al. “Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy”. Am. J. Cardiol. (2011) 107(3): 472–477.
  17. Mornoş, C., and Petrescu, L. “Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist”. Canadian Journal of Physiology and Pharmacology, (2012) 91(8), 601–607.
  18. Khakoo, A., Liu, P., Force, T., et al. “Cardiotoxicity due to cancer therapy”. Tex. Heart Inst. J. (2011) 38(3): 253–256.
  19. Yeh, E., and Bickford, C. “Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management”. J. Am. Coll. Cardiol. (2011) 53(24): 2231–2247
  20. Abdel-Qadir H, Amir E and Thavendiranathan P. “Prevention, detection, and management of chemotherapy-related cardiac dysfunction”. Can J Cardiol. (2016); 32(7):891–899.
  21. Arciniegas Calle M, Sandhu N, Xia H, et al. “Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.” BMC Cancer. (2018); 18(1):1037.
  22. Kitayama, H., Kondo, T., Sugiyama, J., et al. “High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer”, (2017) 24(6), 774–782.
  23. Christenson E, James T, Agrawal V, et al. “Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.” Clin Biochem. (2015); 48(4–5):223–235.
  24. Gripp E, Oliveira G, Feijó L, et al. “Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients during Anthracycline and/or Trastuzumab Treatment”. Arq Bras Cardiol. (2018); 110(2):140–150.
  25. Boyd A., Stoodley, P., Richards, D., and et al. “Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study”. PLOS ONE, (2017) 12(4), e0175544.
  26. Patel N., Chyu C., Satou G. “Left atrial function in children and young adult cancer survivors treated with anthracyclines. Echocardiography” (2018).
  27. Li V., Liu A., So E., “Two- and three-dimensional myocardial strain imaging in the interrogation of sex differences in cardiac mechanics of long-term survivors of childhood cancers”. The International Journal of Cardiovascular Imaging (2018).
  28. Zordoky B, Radin M, Heller L, et al “the interplay between genetic background and sexual dimorphism of doxorubicin- induced Cardiotoxicity”. Cardiooncology (2016) 2:4
  29. Zhang J, Knapton A, Lipshultz SE, et al. “Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats”. Toxicol Pathol (2016) 42:361–375.
  30. Moulin M, Piquereau J, Mateo P, et al. “Sexual dimorphism of doxorubicin mediated cardiotoxicity potential role of energy metabolism remodeling”. Circ Heart Fail (2015) 8:98–108.
  31. Ho E, Brown A, Barrett P, et al. “Subclinical anthracycline- and trastuzumab- induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study”. Heart. (2010); 96: 701±707.
  32. Santoro C., Arpino G., Esposito R., et al. “2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.” European Heart Journal - Cardiovascular Imaging, (2017) 18(8), 930–936.
  33. Rhea I, Uppuluri S, Sawada S, et al. “Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients”. J Am Soc Echocardiogr. (2015); 28(6):667–673.
  34. Blaes A, Rehman A, Vock D, et al. “Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy”. Vasc Health Risk Manag. (2015); 11:591–594.
  35. Advani P., Hoyne J., Moreno-Aspita, A. et al. “High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy.” Chemotherapy, (2017) 62(6), 334–338.
  36. Farsalinos K, Daraban A, Ünlü S, et al. “Head to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI/ASE Inter-Vendor Comparison study”. J Am Soc Echocardiogr (2015); 28:1171–81.
  37. Hu H, Zhang X, Zhang W, et al. “Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor.” Chin Med J (Engl). (2018) ; 131(12):1450–1456.
  38. Jones M., O’Gorman P., Kelly C., et al. “High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.” Annals of Clinical Biochemistry, (2017) 54(1), 149–157.
  39. Sawaya H, Sebag I, Plana J, et al. “Early detection and prediction of cardiotoxicity in chemotherapy-treated patients”. Am J Cardiol (2011); 107:1375-80.
  40. Ky B, Putt M, Sawaya H, et al. “Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab”. J Am Coll Cardiol (2014); 63:809–816.
  41. Yoon G., Telli M., Kao D., et al. “Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?” J Am Coll Cardiol (2010); 56:1644-50.
 

 

 

Statistics
Article View: 349
PDF Download: 262